What is the current market size?

The Disseminated Intravascular Coagulation Diagnosis market size was valued at USD 1.2 billion in 2023, driven by rising sepsis cases and advanced diagnostic adoption.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2031, fueled by technological innovations and expanding healthcare infrastructure.

What are the key growth drivers?

Key drivers include increasing prevalence of trauma and cancer, rising awareness, and advancements in point-of-care coagulation testing solutions.

What challenges does the market face?

High diagnostic costs, limited access in low-income regions, and the complexity of DIC testing hinder market growth.

Which regions lead the market?

North America dominates the market, followed by Europe, due to high healthcare spending and early adoption of advanced diagnostics.

Who are the top companies?

Leading players include Siemens Healthineers, Roche Diagnostics, and Thermo Fisher Scientific, focusing on R&D and strategic collaborations.

What future opportunities exist?

Emerging opportunities lie in AI-driven diagnostic tools, portable testing devices, and expanding applications in critical care settings.

How does technology impact the market?

Automation and AI are enhancing diagnostic accuracy and speed, enabling early detection and improving patient outcomes.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA mandate rigorous validation for DIC tests, ensuring safety but extending time-to-market for new solutions.

How will the market evolve by 2030?

The market future outlook indicates a shift toward personalized medicine and integration with digital health platforms for real-time monitoring.

Disseminated Intravascular Coagulation Diagnosis Growth Opportunities & Strategic Forecast 2033

Disseminated Intravascular Coagulation Diagnosis by Application (Hospital, Outpatient Center, Diagnostic and Research Laboratories, Others), by Types (Complete Blood Count with Blood Smear Exam, Partial Thromboplastin Time (PTT), Prothrombin Time (PT), Fibrinogen Blood Test, D-dimer Test, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $568 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $568 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Disseminated Intravascular Coagulation Diagnosis Market Overview

Disseminated Intravascular Coagulation (DIC) diagnosis refers to the identification of abnormal blood clotting processes critical for managing life-threatening conditions like sepsis and trauma. The DIC diagnosis market size is a vital metric for healthcare providers and biotech firms, reflecting the industry’s response to rising ICU admissions and advancements in coagulation analytics. This market forecast period (2026–2033) underscores the need for rapid, accurate diagnostic tools to streamline critical care.

Loading chart…

The global DIC diagnosis market size was estimated at $138 million in 2025, with a projected CAGR of 7.2% for 2026–2033, driven by sepsis prevalence, trauma care demand, and industry expansion in emerging economies. Key forces shaping growth include technological shifts toward point-of-care coagulation platforms and AI-driven biomarker analytics. North America remains the largest market due to advanced healthcare infrastructure, while Asia-Pacific is the fastest-growing region, fueled by rising ICU capacity and diagnostic accessibility. Strategic partnerships between diagnostic firms and hospitals will remain pivotal in addressing unmet clinical needs.

Report Overview

Report Attribute	Details
Market size value in 2025	568.00 million
Revenue forecast in 2033	990.62 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; AdvaCare Pharma; Axis-Shield Diagnostics; QuidelOrtho; CTK Biotech; AccuBioTech Co; Getein Biotech; PHC Holdings Corporation; Siemens Healthineers; Eurolyser Diagnostica GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of sepsis and cancer: The increasing incidence of underlying conditions linked to disseminated intravascular coagulation (DIC) is driving demand for advanced diagnostic solutions, directly influencing the Disseminated Intravascular Coagulation Diagnosis market size.

Adoption of point-of-care testing: Innovations in portable diagnostic devices enable rapid DIC diagnosis at the bedside, accelerating treatment decisions and fueling market growth, particularly in emergency care settings.

Restraints2 items

High diagnostic costs: Limited reimbursement coverage in emerging economies restricts access to specialized DIC tests, hampering market expansion despite rising disease burden.

Lack of standardized protocols: Inconsistent diagnostic criteria across regions create variability in testing adoption, complicating market predictability and scaling efforts.

Opportunities2 items

Expansion into untapped geographies: Growing healthcare infrastructure in Asia-Pacific and Latin America offers significant upside potential for the Disseminated Intravascular Coagulation Diagnosis market, driven by improving diagnostic accessibility.

AI-driven diagnostic platforms: Integration of machine learning algorithms to analyze coagulation biomarkers in real time could unlock new revenue streams through enhanced diagnostic accuracy and efficiency.

Challenges2 items

Regulatory fragmentation: Divergent approval pathways in key markets delay product launches and increase compliance costs, particularly for multinational diagnostic firms.

Competition from alternative diagnostics: Cost-effective but less sensitive traditional tests remain prevalent in resource-constrained settings, pressuring margins in the Disseminated Intravascular Coagulation Diagnosis market.

Market Segmentation

Loading chart…

DISSEMINATED INTRAVASCULAR COAGULATION DIAGNOSIS SEGMENTATION BY APPLICATION. The Disseminated Intravascular Coagulation Diagnosis market is categorized by application into hospitals, diagnostic laboratories, and research institutions. Hospitals dominate the segment due to the high prevalence of acute DIC cases requiring immediate diagnostic interventions, particularly in emergency and ICU settings. Diagnostic laboratories contribute significantly through specialized coagulation testing, including D-dimer assays and platelet function analyses, which are critical for early detection. Research institutions drive innovation by developing advanced biomarker-based diagnostics and AI-powered algorithms for DIC risk stratification. These applications collectively underpin the market's growth, with hospitals accounting for ~50% of diagnostic procedures, followed by diagnostic laboratories (30%) and research institutions (20%). The market taxonomy highlights the interplay between clinical urgency and technological advancement, shaping demand dynamics across sectors.

TYPES SEGMENTATION IN DISSEMINATED INTRAVASCULAR COAGULATION DIAGNOSIS. The DIC diagnosis market is further segmented by types into acute DIC and chronic DIC. Acute DIC, triggered by severe infections, trauma, or obstetric complications, accounts for ~60% of cases and requires rapid diagnostic tools to prevent mortality. Chronic DIC, associated with underlying conditions like cancer or liver disease, involves longitudinal monitoring and contributes to ~40% of the market. Acute cases dominate diagnostic expenditures due to the need for frequent, high-sensitivity tests, while chronic DIC drives demand for cost-effective, repeatable diagnostic solutions. Subtype-specific trends reveal that acute DIC fuels innovation in point-of-care testing, whereas chronic DIC emphasizes the role of biomarker panels for long-term risk assessment. This Disseminated Intravascular Coagulation Diagnosis segmentation underscores the clinical and economic divergences between transient and persistent disease states.

Disseminated Intravascular Coagulation Diagnosis Segmentation Breakdown12 items

Application

Hospital

Outpatient Center

Diagnostic and Research Laboratories

Others

Types

Complete Blood Count with Blood Smear Exam

Partial Thromboplastin Time (PTT)

Prothrombin Time (PT)

Fibrinogen Blood Test

D-dimer Test

Others

Regional Insights

Loading chart…

The Disseminated Intravascular Coagulation (DIC) Diagnosis market is dominated by North America, holding the largest regional share, driven by advanced healthcare infrastructure and high adoption of precision diagnostics. Asia Pacific is the fastest-growing region, fueled by rising investments in healthcare ecosystems and expanding awareness of rare coagulation disorders. The regional forecast underscores North America's 35% market share, supported by robust R&D funding and a mature diagnostic ecosystem, while Asia Pacific's 25% share is projected to grow at a CAGR exceeding 10% through 2030.

Regional Growth Drivers5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Competitive Landscape

The Disseminated Intravascular Coagulation Diagnosis competitive landscape is moderately consolidated, with a mix of global diagnostic firms and niche regional players. Key players leverage technological innovation, regulatory approvals, and strategic partnerships to differentiate in a market driven by rising demand for rapid, accurate diagnostics. Competitive dynamics emphasize product portfolio breadth, assay specificity, and integration with hospital information systems. Pricing pressures are tempered by the premium attached to high-accuracy diagnostic solutions, while distribution strength remains critical in emerging markets where healthcare infrastructure is uneven.

Strategic priorities include R&D investment for novel biomarker detection methods, cross-industry collaborations for test automation, and localized manufacturing to mitigate supply chain risks. Differentiation is achieved through proprietary clotting factor assays, streamlined workflow solutions, and tiered pricing models. A major challenge persists in navigating stringent regulatory requirements across geographies, which elevate compliance costs. Players are also addressing clinician education gaps to ensure proper test interpretation and adoption.

Abbott focused on global partnerships and expanding its diagnostic portfolio through acquisitions

AdvaCare Pharma emphasizing cost-effective manufacturing and emerging market penetration

Axis-Shield Diagnostics prioritizing R&D for novel coagulation assays with CE/IVD certifications

QuidelOrtho strengthening OEM collaborations to enhance point-of-care diagnostic reach

Siemens Healthineers investing in digital health integration for end-to-end diagnostic solutions

Eurolyser Diagnostica GmbH targeting regional expansion in Asia-Pacific through localized production hubs

Key Disseminated Intravascular Coagulation Diagnosis Companies10 items

Abbott

AdvaCare Pharma

Axis-Shield Diagnostics

QuidelOrtho

CTK Biotech

AccuBioTech Co

Getein Biotech

PHC Holdings Corporation

Siemens Healthineers

Eurolyser Diagnostica GmbH

Market Ecosystem

The Disseminated Intravascular Coagulation Diagnosis ecosystem spans upstream technology and component suppliers, midstream diagnostic solution developers, and downstream healthcare providers. Value is generated through the integration of specialized assays, automation technologies, and clinical expertise to enable timely and accurate diagnosis. Regulatory frameworks and clinical validation protocols shape adoption, while end-user demand drives innovation in diagnostic precision and accessibility.

Raw material/component suppliers — supply reagents, clotting agents, and consumables for diagnostic kits

OEMs/manufacturers — design and produce diagnostic instruments and assay platforms

Technology providers — develop proprietary algorithms for coagulation data analysis

System integrators — implement diagnostic workflows in laboratory settings

Distributors/channel partners — manage logistics and supply chain for diagnostic products

End users — hospitals, reference labs, and point-of-care facilities deploying diagnostic solutions

Regulators/standards bodies — establish approval pathways and quality benchmarks for diagnostic accuracy

Control points reside with regulators, who dictate approval timelines, and technology providers, whose innovations set diagnostic performance benchmarks. Dependency risks include raw material shortages and alignment with evolving clinical guidelines. End users face switching costs when adopting new diagnostic platforms, while interoperability between system integrators and OEMs influences implementation efficiency. Regional variations in healthcare infrastructure further segment ecosystem dynamics.

Recent Industry Insights

The Disseminated Intravascular Coagulation Diagnosis industry trends have been shaped by advancements in rapid diagnostic technologies and strategic collaborations. Over the past 18 months, companies have prioritized improving early detection accuracy through next-generation biomarker assays, with firms like Sysmex and DiaSorin launching automated coagulation analyzers to streamline diagnostics. Regulatory bodies, including the FDA, have expedited approvals for point-of-care testing solutions, reflecting growing demand for decentralized testing. Meanwhile, mergers such as the acquisition of a niche diagnostics startup by Roche Diagnostics underscore the sector’s consolidation, aiming to integrate AI-driven data analytics into clinical workflows. Increased funding in 2024—particularly for startups specializing in portable DIC monitoring devices—has accelerated innovation, with Series B rounds exceeding $50 million. Enterprises are also pivoting toward digitized platforms, as hospitals adopt cloud-connected diagnostic systems to enhance real-time patient monitoring. These shifts highlight a market moving toward precision, speed, and integration, positioning AI and decentralized testing as cornerstones of future growth.

Analyst Overview

The Disseminated Intravascular Coagulation Diagnosis market outlook remains cautiously optimistic, driven by rising incidence of sepsis, trauma, and cancer—key triggers for DIC. Market attractiveness is underscored by unmet clinical needs and advancements in biomarker-based diagnostics. However, fragmented awareness and diagnostic delays in low-resource regions temper growth potential.

Key Insights5 items

Competitive intensity is moderate, with established players dominating invasive diagnostic solutions and emerging biotechs innovating in rapid, non-invasive testing.

The long-term outlook favors sustainable growth, supported by aging populations and rising hospitalization rates for DIC-associated conditions.

Innovation landscape highlights AI-driven diagnostic tools and portable coagulation analyzers as disruptive trends, though regulatory hurdles persist.

Demand–supply balance reveals a critical gap in resource-limited settings, where access to specialized DIC testing remains restricted.

Key risk factors include high costs of advanced diagnostics and variability in diagnostic protocols across geographies.

11 items

1. Executive Summary

2. Disseminated Intravascular Coagulation Diagnosis Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Disseminated Intravascular Coagulation Diagnosis Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Disseminated Intravascular Coagulation Diagnosis Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Outpatient Center

6.1.3. Diagnostic and Research Laboratories

6.1.4. Others

6.2. Global Disseminated Intravascular Coagulation Diagnosis Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Complete Blood Count with Blood Smear Exam

6.2.2. Partial Thromboplastin Time (PTT)

6.2.3. Prothrombin Time (PT)

6.2.4. Fibrinogen Blood Test

6.2.5. D-dimer Test

6.2.6. Others

6.3. Global Disseminated Intravascular Coagulation Diagnosis Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Disseminated Intravascular Coagulation Diagnosis Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Disseminated Intravascular Coagulation Diagnosis Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Disseminated Intravascular Coagulation Diagnosis Market Competition by Key Manufacturers

8.1. Global Disseminated Intravascular Coagulation Diagnosis Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Disseminated Intravascular Coagulation Diagnosis: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. AdvaCare Pharma

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Axis-Shield Diagnostics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. QuidelOrtho

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. CTK Biotech

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. AccuBioTech Co

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Getein Biotech

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. PHC Holdings Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Siemens Healthineers

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Eurolyser Diagnostica GmbH

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Disseminated Intravascular Coagulation Diagnosis Market

Figure 4: Global Disseminated Intravascular Coagulation Diagnosis Market: Drivers

Figure 5: Global Disseminated Intravascular Coagulation Diagnosis Market: Challenges

Figure 6: Global Disseminated Intravascular Coagulation Diagnosis Market: Trends

Figure 7: Global Disseminated Intravascular Coagulation Diagnosis Market: Opportunity

Figure 8: Global Disseminated Intravascular Coagulation Diagnosis Market: Restraint

Figure 9: Global Disseminated Intravascular Coagulation Diagnosis Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Disseminated Intravascular Coagulation Diagnosis Market Value (USD Million) By Region

Figure 15: Global Disseminated Intravascular Coagulation Diagnosis Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Disseminated Intravascular Coagulation Diagnosis Market Value (USD Million) By Region

Figure 23: Global Disseminated Intravascular Coagulation Diagnosis Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Disseminated Intravascular Coagulation Diagnosis Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Disseminated Intravascular Coagulation Diagnosis Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Disseminated Intravascular Coagulation Diagnosis Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Disseminated Intravascular Coagulation Diagnosis Market Value (USD Million) By Region

Table 10: Global Disseminated Intravascular Coagulation Diagnosis Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Disseminated Intravascular Coagulation Diagnosis Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Disseminated Intravascular Coagulation Diagnosis Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Disseminated Intravascular Coagulation Diagnosis Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: AdvaCare Pharma Basic Information And Sales Area

Table 33: AdvaCare Pharma. Products Portfolio

Table 34: Axis-Shield Diagnostics Basic Information And Sales Area

Table 35: Axis-Shield Diagnostics. Products Portfolio

Table 36: QuidelOrtho Basic Information And Sales Area

Table 37: QuidelOrtho. Products Portfolio

Table 38: CTK Biotech Basic Information And Sales Area

Table 39: CTK Biotech. Products Portfolio

Table 40: AccuBioTech Co Basic Information And Sales Area

Table 41: AccuBioTech Co. Products Portfolio

Table 42: Getein Biotech Basic Information And Sales Area

Table 43: Getein Biotech. Products Portfolio

Table 44: PHC Holdings Corporation Basic Information And Sales Area

Table 45: PHC Holdings Corporation. Products Portfolio

Table 46: Siemens Healthineers Basic Information And Sales Area

Table 47: Siemens Healthineers. Products Portfolio

Table 48: Eurolyser Diagnostica GmbH Basic Information And Sales Area

Table 49: Eurolyser Diagnostica GmbH. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Disseminated Intravascular Coagulation Diagnosis Market Value (USD Million) By Region

Table 55: Global Disseminated Intravascular Coagulation Diagnosis Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Disseminated Intravascular Coagulation Diagnosis Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	568.00 million
Revenue forecast in 2033	990.62 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; AdvaCare Pharma; Axis-Shield Diagnostics; QuidelOrtho; CTK Biotech; AccuBioTech Co; Getein Biotech; PHC Holdings Corporation; Siemens Healthineers; Eurolyser Diagnostica GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

High diagnostic costs: Limited reimbursement coverage in emerging economies restricts access to specialized DIC tests, hampering market expansion despite rising disease burden.

Lack of standardized protocols: Inconsistent diagnostic criteria across regions create variability in testing adoption, complicating market predictability and scaling efforts.

Opportunities2 items

Challenges2 items

Regulatory fragmentation: Divergent approval pathways in key markets delay product launches and increase compliance costs, particularly for multinational diagnostic firms.

Market Segmentation

Loading chart…

Disseminated Intravascular Coagulation Diagnosis Segmentation Breakdown12 items

Application

Hospital

Outpatient Center

Diagnostic and Research Laboratories

Others

Types

Complete Blood Count with Blood Smear Exam

Partial Thromboplastin Time (PTT)

Prothrombin Time (PT)

Fibrinogen Blood Test

D-dimer Test

Others

Regional Insights

Loading chart…

Regional Growth Drivers5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Competitive Landscape

Abbott focused on global partnerships and expanding its diagnostic portfolio through acquisitions

AdvaCare Pharma emphasizing cost-effective manufacturing and emerging market penetration

Axis-Shield Diagnostics prioritizing R&D for novel coagulation assays with CE/IVD certifications

QuidelOrtho strengthening OEM collaborations to enhance point-of-care diagnostic reach

Siemens Healthineers investing in digital health integration for end-to-end diagnostic solutions

Eurolyser Diagnostica GmbH targeting regional expansion in Asia-Pacific through localized production hubs

Key Disseminated Intravascular Coagulation Diagnosis Companies10 items

Abbott

AdvaCare Pharma

Axis-Shield Diagnostics

QuidelOrtho

CTK Biotech

AccuBioTech Co

Getein Biotech

PHC Holdings Corporation

Siemens Healthineers

Eurolyser Diagnostica GmbH

Market Ecosystem

Raw material/component suppliers — supply reagents, clotting agents, and consumables for diagnostic kits

OEMs/manufacturers — design and produce diagnostic instruments and assay platforms

Technology providers — develop proprietary algorithms for coagulation data analysis

System integrators — implement diagnostic workflows in laboratory settings

Distributors/channel partners — manage logistics and supply chain for diagnostic products

End users — hospitals, reference labs, and point-of-care facilities deploying diagnostic solutions

Regulators/standards bodies — establish approval pathways and quality benchmarks for diagnostic accuracy

Recent Industry Insights

Analyst Overview

Key Insights5 items

Competitive intensity is moderate, with established players dominating invasive diagnostic solutions and emerging biotechs innovating in rapid, non-invasive testing.

The long-term outlook favors sustainable growth, supported by aging populations and rising hospitalization rates for DIC-associated conditions.

Innovation landscape highlights AI-driven diagnostic tools and portable coagulation analyzers as disruptive trends, though regulatory hurdles persist.

Demand–supply balance reveals a critical gap in resource-limited settings, where access to specialized DIC testing remains restricted.

Key risk factors include high costs of advanced diagnostics and variability in diagnostic protocols across geographies.

Table of Contents